Literature DB >> 2491771

Effects of flecainide on the atrial defibrillation threshold.

I C Van Gelder1, H J Crijns, W H Van Gilst, C D De Langen, L M Van Wijk, K I Lie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2491771     DOI： 10.1016/0002-9149(89)91090-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  6 in total

Review 1.  Atrial fibrillation. The therapeutic options.

Authors:  R V Lewis
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Low energy internal cardioversion of atrial fibrillation resistant to transthoracic shocks.

Authors:  S M Sopher; F D Murgatroyd; A K Slade; I Blankoff; E Rowland; D E Ward; A J Camm
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

3.  Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation.

Authors:  Anna Nergärdh; Rolf Nordlander; Mats Frick
Journal:  Clin Cardiol       Date:  2006-02       Impact factor: 2.882

Review 4.  Interactions of antiarrhythmic drugs with implantable defibrillator therapy for atrial and ventricular tachyarrhythmias.

Authors:  R B Krol; S Saksena; A Prakash
Journal:  Curr Cardiol Rep       Date:  1999-11       Impact factor: 2.931

5.  Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS Study Group.

Authors:  H J Crijns; A T Gosselink; K I Lie
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727

6.  Intravenous propafenone: efficacy and safety in the conversion to sinus rhythm of recent onset atrial fibrillation--a single-blind placebo-controlled study.

Authors:  F Bellandi; R P Dabizzi; F Cantini; M D Natale; L Niccoli
Journal:  Cardiovasc Drugs Ther       Date:  1996-05       Impact factor: 3.727
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.